| Literature DB >> 8527840 |
K Koths1.
Abstract
Recombinant proteins that have survived the challenges of process development and clinical trials are becoming blockbuster medical products. Growth factors, enzymes and antibodies are being improved by mutational approaches, fused with other proteins, and even chemically modified in vitro. Drug development and testing approaches have advanced, and proteins produced in transgenic animals are new becoming available. Future protein products might include cancer vaccines and therapies for a variety of genetic diseases, but alternative treatments involving gene therapy or small synthetic compounds will provide competition.Entities:
Mesh:
Substances:
Year: 1995 PMID: 8527840 DOI: 10.1016/0958-1669(95)80112-x
Source DB: PubMed Journal: Curr Opin Biotechnol ISSN: 0958-1669 Impact factor: 9.740